At the time of writing, ProQR Therapeutics N.V [PRQR] stock is trading at $1.75, up 2.34%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The PRQR shares have gain 10.76% over the last week, with a monthly amount drifted -18.22%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Evercore ISI started tracking the stock with Outperform rating on April 29, 2025, and set its price target to $5. On March 10, 2025, upgrade upgraded it’s rating to Buy but maintained its price target of $4 on the stock. Oppenheimer started tracking the stock assigning a Outperform rating and suggested a price target of $15 on January 10, 2025. Raymond James upgraded its rating to a Strong Buy and raised its price target to $14 on October 29, 2024. Chardan Capital Markets upgraded its rating to Buy for this stock on November 08, 2023, but kept the price target unchanged to $2. In a note dated March 30, 2023, JMP Securities upgraded an Mkt Outperform rating on this stock and boosted its target price from $1.50 to $5.
For the past year, the stock price of ProQR Therapeutics N.V fluctuated between $1.07 and $3.10. Currently, Wall Street analysts expect the stock to reach $3.63 within the next 12 months. ProQR Therapeutics N.V [NASDAQ: PRQR] shares were valued at $1.75 at the most recent close of the market. An investor can expect a potential return of 107.43% based on the average PRQR price forecast.
Analyzing the PRQR fundamentals
According to ProQR Therapeutics N.V [NASDAQ:PRQR], the company’s sales were 17.05M for trailing twelve months, which represents an -20.23% plunge. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -2.86%, Pretax Profit Margin comes in at -2.73%, and Net Profit Margin reading is -2.74%. To continue investigating profitability, this company’s Return on Assets is posted at -0.34, Equity is -0.57 and Total Capital is -0.49. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.29.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that ProQR Therapeutics N.V [NASDAQ:PRQR] has a current ratio of 3.36. As well, the Quick Ratio is 3.36, while the Cash Ratio is 3.23. Considering the valuation of this stock, the price to sales ratio is 10.80, the price to book ratio is 2.75.
